Physician profile

Stephen E Kathman

Physician Assistant · Vandalia, OH

NPI 1144566613

$905.27

in general payments reported to CMS, 2019-2025

8 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$905.27

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Phathom Pharmaceuticals, INC. $266.34 2024 Voquezna
Madrigal Pharmaceuticals $190.36 2024 Rezdiffra, Resmetirom
Janssen Biotech, INC. $117.20 2024 Stelara, Tremfya
Genzyme Corporation $111.30 2024
Abbvie INC. $86.08 2024
Takeda Pharmaceuticals U.S.A., INC. $71.60 2024 Entyvio, Eohilia
Salix Pharmaceuticals, A Division of Bausch Health US, LLC $37.25 2024 Xifaxan
Regeneron Healthcare Solutions, INC. $25.14 2024 Dupixent

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Stephen E Kathman

$905.27

in general payments reported 2019-2025

Years
2024
Top company
Phathom Pharmaceuticals, INC.

https://glasscript.com/doctor/10677598/stephen-e-kathman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.